Study,Number of Randomized Patients,Conclusion,Primary Outcome,Results for the Primary Outcome,Blinding,Comparator,Link to Article
"Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. (International Breast Cancer Study Group) , Partridge et al., NEJM, 2023/05/03",516,Temporary interruption of endocrine therapy to attempt pregnancy did not confer a greater short-term risk of breast cancer events than that in the external control cohort,Number of Breast Cancer Events,"3-year incidence of breast cancer events was 8.9% (95% CI, 6.3 to 11.6) in the treatment-interruption group and 9.2% (95% CI, 7.6 to 10.8) in the control cohort",Unspecified,Treatment-Interruption Group vs. External Control Cohort,https://pubmed.ncbi.nlm.nih.gov/37133584/?format=pubmed,
"Prednisone vs Placebo and Live Birth in Patients With Recurrent Implantation Failure Undergoing In Vitro Fertilization: A Randomized Clinical Trial., Sun et al., JAMA, 2023/05/02",715,Treatment with prednisone did not improve live birth rate compared with placebo. Data suggested that the use of prednisone may increase the risk of preterm delivery and biochemical pregnancy loss.,Live birth,"Live birth occurred among 37.8% of women (135 of 357) in the prednisone group vs 38.8% of women (139 of 358) in the placebo group (absolute difference, -1.0% [95% CI, -8.1% to 6.1%]; relative ratio [RR], 0.97 [95% CI, 0.81 to 1.17]; P = .78).",Double-blind,Prednisone (n=357) vs. Placebo (n=358),https://pubmed.ncbi.nlm.nih.gov/37129654/?format=pubmed,
"Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers. (BRACE) , Pittet et al., NEJM, 2023/04/26",3988,Vaccination with BCG-Denmark did not result in a lower risk of Covid-19 among health care workers than placebo.,Symptomatic Covid-19 and severe Covid-19,"Risk of symptomatic Covid-19 by 6 months was 14.7% in the BCG group and 12.3% in the placebo group (risk difference, 2.4 percentage points; 95% CI, -0.7 to 5.5; P = 0.13). Risk of severe Covid-19 by 6 months was 7.6% in the BCG group and 6.5% in the placebo group (risk difference, 1.1 percentage points; 95% CI, -1.2 to 3.5; P = 0.34).",Double-blind,BCG-Denmark vaccine vs. saline placebo,https://pubmed.ncbi.nlm.nih.gov/37099341/?format=pubmed,
"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. (PROTECT) , Heerspink et al., Lancet, 2023/04/04",404,Sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy.,Change from baseline to week 36 in urine protein-creatinine ratio,"Sparsentan (-49.8%) vs. Irbesartan (-15.1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0.59; 95% CI 0.51-0.69; p<0.0001)",Double-blind,Sparsentan vs. Irbesartan,https://pubmed.ncbi.nlm.nih.gov/37015244/?format=pubmed,
"Facilitating Shared Decision Making Among Black Patients at Risk for Sudden Cardiac Arrest : A Randomized Clinical Trial., Thomas et al., Annals of internal medicine, 2023/04/03",330,A video-based decision support tool increased patient knowledge but did not increase assent to ICD implantation.,Decision regarding ICD implantation,"Assent to ICD implantation was 58.6% in the video group compared with 59.4% in the usual care group (difference, -0.8 percentage point [95% CI, -13.2 to 11.1 percentage points])",Unspecified,Video group vs. Usual Care group,https://pubmed.ncbi.nlm.nih.gov/37011387/?format=pubmed,
"Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study., Kip et al., Annals of internal medicine, 2023/04/03","8,706",Early mAb Treatment among Outpatients with COVID-19 is Associated with Lower Risk for Hospitalization or Death for Various mAb Products and SARS-CoV-2 Variants.,Hospitalization or Death at 28 Days,"4.6% in Treated Patients and 7.6% in Nontreated Control Patients (RR, 0.61 [95% CI, 0.50 to 0.74])",Unspecified,Treated Patients vs. Nontreated Control Group,https://pubmed.ncbi.nlm.nih.gov/37011399/?format=pubmed,
"Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study., Kip et al., Annals of internal medicine, 2023/04/03","8,706",Early mAb treatment among outpatients with COVID-19 is associated with lower risk for hospitalization or death for various mAb products and SARS-CoV-2 variants.,Hospitalization or death at 28 days,"4.6% in treated patients and 7.6% in nontreated control patients (risk ratio [RR], 0.61 [95% CI, 0.50 to 0.74])",Unspecified,Treated patients vs. nontreated control group,https://pubmed.ncbi.nlm.nih.gov/37011399/?format=pubmed,
"Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial. (MR) , Olthuis et al., Lancet, 2023/03/29",535,"Endovascular Treatment was efficacious and safe for patients with ischaemic stroke caused by an anterior circulation large-vessel occlusion who presented 6-24 h from onset or last seen well, and who were selected on the basis of the presence of collateral flow on CTA.",Modified Rankin Scale (mRS) Score at 90 Days,Median mRS Score at 90 Days was lower in Endovascular Treatment Group (3 [IQR 2-5]) than Control Group (4 [2-6]); Adjusted Common Odds Ratio (OR) of 1.67 (95% CI 1.20-2.32),Unspecified,Endovascular Treatment vs. No Endovascular Treatment,https://pubmed.ncbi.nlm.nih.gov/37003289/?format=pubmed,
"Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial. (MR) , Olthuis et al., Lancet, 2023/03/29",535,Endovascular Treatment was Efficacious and Safe for Patients with Ischemic Stroke Caused by Anterior Circulation Large-Vessel Occlusion Who Presented 6-24 Hours from Onset or Last Seen Well and Who Were Selected on the Basis of the Presence of Collateral Flow on CTA,Modified Rankin Scale (mRS) Score at 90 Days,Median mRS Score at 90 Days was Lower in Endovascular Treatment Group than Control Group (3 vs 4); Adjusted Common OR 1.67 (95% CI 1.20-2.32),Unspecified,Endovascular Treatment vs No Endovascular Treatment,https://pubmed.ncbi.nlm.nih.gov/37003289/?format=pubmed,
"Acute Effects of Coffee Consumption on Health among Ambulatory Adults., Marcus et al., NEJM, 2023/03/22",100,The consumption of caffeinated coffee did not result in significantly more daily premature atrial contractions than the avoidance of caffeine.,Mean number of daily premature atrial contractions,"58 daily premature atrial contractions with caffeinated coffee vs. 53 daily events on days when caffeine was avoided (rate ratio, 1.09; 95% confidence interval [CI], 0.98 to 1.20; P = 0.10)",Unspecified,Caffeinated coffee vs. no caffeine consumption,https://pubmed.ncbi.nlm.nih.gov/36947466/?format=pubmed,
"Acute Effects of Coffee Consumption on Health among Ambulatory Adults., Marcus et al., NEJM, 2023/03/22",100,Consumption of caffeinated coffee did not result in significantly more daily premature atrial contractions than the avoidance of caffeine.,Mean Number of Daily Premature Atrial Contractions,"58 daily premature atrial contractions with caffeinated coffee vs. 53 daily events with avoidance of caffeine (rate ratio, 1.09; 95% CI, 0.98 to 1.20; P = 0.10)",Unspecified,Caffeinated Coffee vs. Avoidance of Caffeine,https://pubmed.ncbi.nlm.nih.gov/36947466/?format=pubmed,
"Effectiveness of the Family Heart Talk Communication Tool in Improving Family Member Screening for Dilated Cardiomyopathy: Results of a Randomized Trial. (DCM) , Kinnamon et al., Circulation, 2023/03/20","1241 probands, 2230 eligible first-degree relatives in the Family Heart Talk arm, 2416 in the control arm",A booklet that can be provided to patients with dilated cardiomyopathy by clinicians with minimal additional time investment was effective in increasing cardiovascular clinical screening among first-degree relatives of these patients.,Completion of screening initiated within 12 months after proband enrollment,"19.5% of eligible first-degree relatives completed screening in the Family Heart Talk arm vs. 16.0% in the control arm (odds ratio, 1.30 [1-sided 95% CI, 1.08-])",Unspecified,Family Heart Talk arm vs. control arm,https://pubmed.ncbi.nlm.nih.gov/36938756/?format=pubmed,
"Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization. (ACTIV-4C) , Wang et al., Annals of internal medicine, 2023/03/20",1217,"The incidence of death or thromboembolism was low in this cohort of patients discharged after hospitalization with COVID-19, but the results were imprecise and the study was inconclusive","30-day composite of death, arterial thromboembolism, and venous thromboembolism","Incidence of the primary end point was 2.13% (95% CI, 1.14 to 3.62) in the apixaban group and 2.31% (CI, 1.27 to 3.84) in the placebo group",Double-blind,Apixaban vs. Placebo,https://pubmed.ncbi.nlm.nih.gov/36940444/?format=pubmed,
"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study., Lederman et al., Lancet, 2023/03/16",2205,Fezolinetant is a non-hormonal treatment for vasomotor symptoms associated with menopause.,Mean change in frequency and severity of vasomotor symptoms from baseline to weeks 4 and 12,Fezolinetant 30 mg and 45 mg significantly reduced the frequency and severity of vasomotor symptoms at week 4 and week 12 compared to placebo,Unspecified,"Placebo, Fezolinetant 30 mg, Fezolinetant 45 mg",https://pubmed.ncbi.nlm.nih.gov/36924778/?format=pubmed,
"Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes. (PEDAP) , Wadwa et al., NEJM, 2023/03/15",102,The glucose level was in the target range for a greater percentage of time with a closed-loop system than with standard care.,Percentage of time that the glucose level was in the target range of 70 to 180 mg per deciliter,"Mean percentage of time that the glucose level was within the target range increased from 56.7+-18.0% at baseline to 69.3+-11.1% in the closed-loop group and from 54.9+-14.7% to 55.9+-12.6% in the standard-care group (mean adjusted difference, 12.4 percentage points [equivalent to approximately 3 hours per day]; 95% confidence interval, 9.5 to 15.3; P<0.001).",Unspecified,Closed-loop system of insulin delivery vs. standard care,https://pubmed.ncbi.nlm.nih.gov/36920756/?format=pubmed,
"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. (PROMINENT,) , Ridker et al., Lancet, 2023/03/09","31,245",Inflammation is a stronger predictor for risk of future cardiovascular events and death than cholesterol.,"Major Adverse Cardiovascular Events, Cardiovascular Death, and All-Cause Death","Adjusted HR 1*07, 95% CI 0*98-1*17; p=0*11",Unspecified,"PROMINENT, REDUCE-IT, and STRENGTH trials",https://pubmed.ncbi.nlm.nih.gov/36893777/?format=pubmed,
"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. (PROMINENT,) , Ridker et al., Lancet, 2023/03/09","31,245",Inflammation was a stronger predictor for risk of future cardiovascular events and death than cholesterol.,"Major Adverse Cardiovascular Events, Cardiovascular Mortality, and All-Cause Mortality","Residual inflammatory risk was significantly associated with incident major adverse cardiovascular events (highest high-sensitivity CRP quartile vs lowest high-sensitivity CRP quartile, adjusted HR 1*31, 95% CI 1*20-1*43; p<0*0001), cardiovascular mortality (2*68, 2*22-3*23; p<0*0001), and all-cause mortality (2*42, 2*12-2*77; p<0*0001). By contrast, the relationship of residual cholesterol risk was neutral for major adverse cardiovascular events (highest LDLC quartile vs lowest LDLC quartile, adjusted HR 1*07, 95% CI 0*98-1*17; p=0*11), and of low magnitude for cardiovascular death (1*27, 1*07-1*50; p=0*0086) and all-cause death (1*16, 1*03-1*32; p=0*025).",Unspecified,"PROMINENT (n=9988), REDUCE-IT (n=8179), and STRENGTH (n=13 078) trials",https://pubmed.ncbi.nlm.nih.gov/36893777/?format=pubmed,
"Electronic nudges to increase influenza vaccination uptake in Denmark: a nationwide, pragmatic, registry-based, randomised implementation trial., Johansen et al., Lancet, 2023/03/08","964,870",Electronically delivered letters highlighting potential cardiovascular benefits of influenza vaccination or sent again as a reminder significantly increased vaccination uptake across Denmark.,"Receipt of influenza vaccination on or before Jan 1, 2023","Compared with usual care, influenza vaccination rates were higher in the group receiving an electronic letter highlighting potential cardiovascular benefits of vaccination (81*00% vs 80*12%; difference 0*89 percentage points [99*55% CI 0*29-1*48]; p<0*0001) and the group receiving repeated letters at randomisation and at day 14 (80*85% vs 80*12%; difference 0*73 percentage points [0*13-1*34]; p=0*0006).",Unspecified,Usual Care vs 9 different electronic letters,https://pubmed.ncbi.nlm.nih.gov/36889332/?format=pubmed,
"Electronic nudges to increase influenza vaccination uptake in Denmark: a nationwide, pragmatic, registry-based, randomised implementation trial., Johansen et al., Lancet, 2023/03/08","964,870",Electronically delivered letters highlighting potential cardiovascular benefits of influenza vaccination or sent again as a reminder significantly increased vaccination uptake across Denmark.,"Receipt of influenza vaccination on or before Jan 1, 2023","Compared with usual care, influenza vaccination rates were higher in the group receiving an electronic letter highlighting potential cardiovascular benefits of vaccination (81*00% vs 80*12%; difference 0*89 percentage points [99*55% CI 0*29-1*48]; p<0*0001) and the group receiving repeated letters at randomisation and at day 14 (80*85% vs 80*12%; difference 0*73 percentage points [0*13-1*34]; p=0*0006).",Unspecified,Usual Care vs 9 different electronic letters,https://pubmed.ncbi.nlm.nih.gov/36889332/?format=pubmed,
"Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial. (BIOVASC) , Diletti et al., Lancet, 2023/03/08",1525,"Immediate complete revascularisation is a viable option for patients with acute coronary syndrome and multivessel disease, as it is non-inferior to staged complete revascularisation and is associated with a reduction in myocardial infarction and unplanned ischaemia-driven revascularisation.","Composite of all-cause mortality, myocardial infarction, any unplanned ischaemia-driven revascularisation, or cerebrovascular events at 1 year after the index procedure",Immediate complete revascularisation was non-inferior to staged complete revascularisation for the primary composite outcome and was associated with a reduction in myocardial infarction and unplanned ischaemia-driven revascularisation,Unspecified,Immediate complete revascularisation vs. staged complete revascularisation,https://pubmed.ncbi.nlm.nih.gov/36889333/?format=pubmed,
"In adults with acute HF, high-intensity care vs. usual care reduced a composite of death or HF readmission at 180 d., Levine et al., Annals of internal medicine, 2023/03/06","Open-label, randomised",,"Results showed that up-titration of guideline-directed medical therapies for acute heart failure was safe, tolerable, and efficacious.","Up-titration of guideline-directed medical therapies for acute heart failure is safe, tolerable, and efficacious.","Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure",Unspecified,https://pubmed.ncbi.nlm.nih.gov/36877970/?format=pubmed,
"Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial. (COORDINATE-Diabetes Site Investigators) , Pagidipati et al., JAMA, 2023/03/06",1049,"A coordinated, multifaceted intervention increased prescription of 3 groups of evidence-based therapies in adults with type 2 diabetes and atherosclerotic cardiovascular study.",Proportion of participants prescribed all 3 groups of recommended therapies at 6 to 12 months after enrollment,"Intervention Group (37.9%) vs. Usual Care Group (14.5%), difference of 23.4% (adjusted odds ratio [OR], 4.38 [95% CI, 2.49 to 7.71]; P < .001)",Unspecified,Intervention Group (n=459) vs. Usual Care Group (n=590),https://pubmed.ncbi.nlm.nih.gov/36877177/?format=pubmed,
"Intravascular Imaging-Guided or Angiography-Guided Complex PCI. (RENOVATE-COMPLEX-PCI) , Lee et al., NEJM, 2023/03/06",,Error,Error,Error,Error,"1 ratio to intravascular imaging-guided PCI or angiography-guided PCI. The primary end point was a composite of death from cardiac causes, target-vessel-related myocardial infarction, or clinically driven target-vessel revascularization. At a median follow-up of 2.1 years, intravascular imaging-guided PCI led to a lower risk of a composite of death from cardiac causes, target-vessel-related myocardial infarction, or clinically driven target-vessel revascularization than angiography-guided PCI (hazard ratio, 0.64; 95% confidence interval, 0.45 to 0.89; P = 0.008).",https://pubmed.ncbi.nlm.nih.gov/36876735/?format=pubmed,
"Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. (STELLAR) , Hoeper et al., NEJM, 2023/03/06",163 (sotatercept) and 160 (placebo),Sotatercept resulted in a greater improvement in exercise capacity than placebo,Change from baseline at week 24 in the 6-minute walk distance,"Median change from baseline at week 24 in the 6-minute walk distance was 34.4 m (95% CI, 33.0 to 35.5) in the sotatercept group and 1.0 m (95% CI, -0.3 to 3.5) in the placebo group",Double-blind,Sotatercept vs. Placebo,https://pubmed.ncbi.nlm.nih.gov/36877098/?format=pubmed,
"Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial. (COORDINATE-Diabetes Site Investigators) , Pagidipati et al., JAMA, 2023/03/06",1049,"A coordinated, multifaceted intervention increased prescription of 3 groups of evidence-based therapies in adults with type 2 diabetes and atherosclerotic cardiovascular study.",Proportion of participants prescribed all 3 groups of recommended therapies at 6 to 12 months after enrollment,"Intervention Group (173/457 [37.9%]) vs. Usual Care Group (85/588 [14.5%]), Difference of 23.4% (adjusted odds ratio [OR], 4.38 [95% CI, 2.49 to 7.71]; P < .001)",Unspecified,Intervention Group (n=459) vs. Usual Care Group (n=590),https://pubmed.ncbi.nlm.nih.gov/36877177/?format=pubmed,
"Transcatheter Repair for Patients with Tricuspid Regurgitation. (TRILUMINATE) , Sorajja et al., NEJM, 2023/03/06",350,"Tricuspid TEER was safe, reduced the severity of tricuspid regurgitation, and was associated with an improvement in quality of life.",Hierarchical composite of death from any cause or tricuspid-valve surgery; hospitalization for heart failure; and an improvement in quality of life as measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ),TEER group had a win ratio of 1.48 (95% CI 1.06 to 2.13; P=0.02) with a mean increase in KCCQ score of 12.3+-1.8 points compared to 0.6+-1.8 points in the control group (P<0.001),Unspecified,TEER vs. medical therapy (control),https://pubmed.ncbi.nlm.nih.gov/36876753/?format=pubmed,
"In adults with acute HF, high-intensity care vs. usual care reduced a composite of death or HF readmission at 180 d., Levine et al., Annals of internal medicine, 2023/03/06","Open-label, randomised",,"Improved safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure compared to the control group (p<0.0001).","Up-titration of guideline-directed medical therapies for acute heart failure is safe, tolerable and effective.","Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure",Unspecified,https://pubmed.ncbi.nlm.nih.gov/36877970/?format=pubmed,
"Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. (STELLAR) , Hoeper et al., NEJM, 2023/03/06",163 (Sotatercept) and 160 (Placebo),Sotatercept resulted in a greater improvement in exercise capacity (as assessed by the 6-minute walk test) than placebo.,Change from baseline at week 24 in the 6-minute walk distance,"Median change from baseline at week 24 in the 6-minute walk distance was 34.4 m (95% CI, 33.0 to 35.5) in the sotatercept group and 1.0 m (95% CI, -0.3 to 3.5) in the placebo group; Hodges-Lehmann estimate of the difference between the sotatercept and placebo groups in the change from baseline at week 24 in the 6-minute walk distance was 40.8 m (95% CI, 27.5 to 54.1; P<0.001)",Double-blind,Sotatercept vs. Placebo,https://pubmed.ncbi.nlm.nih.gov/36877098/?format=pubmed,
"Eliminating Medication Copayments for Low-Income Older Adults at High Cardiovascular Risk: A Randomized Controlled Trial. (Interdisciplinary Chronic Disease Collaboration) , Campbell et al., Circulation, 2023/03/05",4761,"Eliminating copayments did not improve clinical outcomes or reduce health care costs, despite a modest improvement in adherence to medications.","Composite of death, myocardial infarction, stroke, coronary revascularization, and cardiovascular-related hospitalizations over a 3-year follow-up","No reduction in rate (521 versus 533 events, incidence rate ratio 0.84 [95% CI, 0.66-1.07], P=0.162)",Unspecified,Copayment elimination versus usual copayment,https://pubmed.ncbi.nlm.nih.gov/36871215/?format=pubmed,
"Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial. (CRHCP) , He et al., Lancet, 2023/03/05","33,995",The non-physician community health-care provider-led intensive blood pressure intervention is effective in reducing cardiovascular disease and death.,"Composite outcome of myocardial infarction, stroke, heart failure requiring hospitalisation, and cardiovascular disease death during the 36-month follow-up","Fewer patients in the intervention group than the usual care group had a primary outcome (1*62% vs 2*40% per year; hazard ratio [HR] 0*67, 95% CI 0*61-0*73; p<0*0001)",Unspecified,Non-physician community health-care provider-led intervention vs. usual care,https://pubmed.ncbi.nlm.nih.gov/36871573/?format=pubmed,
"Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial., Han et al., Circulation, 2023/03/05",2013,3- to 6-month DAPT was noninferior to 12-month DAPT for net adverse clinical event.,Net Adverse Clinical Event,"3.7% in 3- to 6-month DAPT group and 4.1% in 12-month DAPT group; noninferiority of 3- to 6-month DAPT group to 12-month DAPT group met (absolute risk difference, -0.4% [1-sided 95% CI, -% to 1.1%]; P<0.001 for noninferiority)",Unspecified,3- to 6-month DAPT vs 12-month DAPT,https://pubmed.ncbi.nlm.nih.gov/36871230/?format=pubmed,
"Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial. (CRHCP) , He et al., Lancet, 2023/03/05","33,995",The non-physician community health-care provider-led intensive blood pressure intervention is effective in reducing cardiovascular disease and death.,"Composite outcome of myocardial infarction, stroke, heart failure requiring hospitalisation, and cardiovascular disease death","Fewer patients in the intervention group than the usual care group had a primary outcome (1.62% vs 2.40% per year; hazard ratio [HR] 0.67, 95% CI 0.61-0.73; p<0.0001)",Unspecified,Non-physician community health-care provider-led intervention vs. usual care,https://pubmed.ncbi.nlm.nih.gov/36871573/?format=pubmed,
"Effect of Electronic Nudges on Influenza Vaccination Rate in Older Adults With Cardiovascular Disease: Prespecified Analysis of the NUDGE-FLU Trial., Modin et al., Circulation, 2023/03/05","964,870",Electronic letter interventions emphasizing the potential cardiovascular benefits of influenza vaccination and using a reminder letter strategy were similarly beneficial in increasing influenza vaccination rates among older adults with and without CVD and across cardiovascular subgroups.,"Receipt of an influenza vaccine on or before January 1, 2023",83.1% of participants with CVD versus 79.2% of participants without CVD received an influenza vaccination (P<0.001),Unspecified,Usual care vs. 9 electronic letters,https://pubmed.ncbi.nlm.nih.gov/36871213/?format=pubmed,
"On-Site Computed Tomography-Derived Fractional Flow Reserve to Guide Management of Patients With Stable Coronary Artery Disease: The TARGET Randomized Trial., Yang et al., Circulation, 2023/03/04",1216,"On-site CT-FFR using machine learning reduced the proportion of patients with stable coronary artery disease undergoing invasive coronary angiography without obstructive disease or requiring intervention within 90 days, but increased revascularization overall without improving symptoms or quality of life, or reducing major adverse cardiovascular events.",Proportion of patients undergoing invasive coronary angiography without obstructive coronary artery disease or with obstructive disease who did not undergo intervention within 90 days,28.3% (119/421) in the CT-FFR care group vs. 46.2% (223/483) in the standard care group (P<0.001),Unspecified,on-site CT-FFR care pathway using machine learning vs. standard care,https://pubmed.ncbi.nlm.nih.gov/36870065/?format=pubmed,
"Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial. (RADIANCE) , Azizi et al., JAMA, 2023/02/28",,Error,Error,Error,Error,"1 to undergo ultrasound renal denervation or a sham procedure. The primary outcome was the mean change in daytime ambulatory SBP at 2 months, which was significantly improved with ultrasound renal denervation (-7.9 mm Hg [SD, 11.6 mm Hg]) vs the sham procedure (-1.8 mm Hg [SD, 9.5 mm Hg]) with no major adverse events reported in either group.",https://pubmed.ncbi.nlm.nih.gov/36853250/?format=pubmed,
"Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial. (RADIANCE) , Azizi et al., JAMA, 2023/02/28",1038,Ultrasound renal denervation reduced daytime ambulatory SBP at 2 months in the absence of antihypertensive medications vs a sham procedure without postprocedural major adverse events.,Mean change in daytime ambulatory SBP at 2 months,"Reduction in daytime ambulatory SBP was greater with ultrasound renal denervation (mean, -7.9 mm Hg [SD, 11.6 mm Hg]) vs the sham procedure (mean, -1.8 mm Hg [SD, 9.5 mm Hg]) (baseline-adjusted between-group difference, -6.3 mm Hg [95% CI, -9.3 to -3.2 mm Hg], P < .001)",Unspecified,Ultrasound renal denervation vs a sham procedure,https://pubmed.ncbi.nlm.nih.gov/36853250/?format=pubmed,
"Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial., Gerstein et al., Circulation, 2023/02/21","3,722",Adding either 4 mg or 6 mg weekly of the glucagon-like peptide-1 receptor agonist efpeglenatide to usual care reduced major adverse cardiovascular events (MACE) in people with type 2 diabetes at high cardiovascular risk. Titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to high doses may maximize their cardiovascular and renal benefits.,Major Adverse Cardiovascular Events (MACE),"9.2% of participants assigned to placebo, 6.2% of participants assigned to 6 mg of efpeglenatide (hazard ratio [HR], 0.65 [95% CI, 0.5-0.86]; P=0.0027), and 7.7% assigned to 4 mg of efpeglenatide (HR, 0.82 [95% CI, 0.63-1.06]; P=0.14).",Unspecified,"Placebo, 4 mg, 6 mg of efpeglenatide",https://pubmed.ncbi.nlm.nih.gov/36802715/?format=pubmed,
"Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial., Gerstein et al., Circulation, 2023/02/21","3,876","Adding either 4 mg or 6 mg weekly of the glucagon-like peptide-1 receptor agonist efpeglenatide to usual care reduces major adverse cardiovascular events (MACE) in people with type 2 diabetes at high cardiovascular risk, with the greatest benefit seen with the 6 mg dose.",Major adverse cardiovascular events (MACE),"9.2% of participants assigned to placebo experienced MACE, 6.2% of participants assigned to 6 mg of efpeglenatide experienced MACE (hazard ratio [HR], 0.65 [95% CI, 0.5-0.86]; P=0.0027), and 7.7% of participants assigned to 4 mg of efpeglenatide experienced MACE (HR, 0.82 [95% CI, 0.63-1.06]; P=0.14).",Unspecified,"Placebo, 4 mg, 6 mg",https://pubmed.ncbi.nlm.nih.gov/36802715/?format=pubmed,
"Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE., Gaba et al., Circulation, 2023/02/13","27,564","Lower LDL-C levels, down to <20 mg/dL, associated with lower risk of cardiovascular outcomes with no significant safety concerns","Composite of cardiovascular death, myocardial infarction, stroke, hospital admission for unstable angina or coronary revascularization",Lower achieved LDL-C levels-down to very low levels <20 mg/dL-associated with a lower risk of the primary efficacy end point (adjusted P(trend)<0.0001),Unspecified,evolocumab vs. placebo,https://pubmed.ncbi.nlm.nih.gov/36779348/?format=pubmed,
"Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE., Gaba et al., Circulation, 2023/02/13",,Error,Error,Error,Error,"2) This was a randomized, open-label study of 27,564 patients with stable atherosclerotic cardiovascular disease, comparing evolocumab to placebo. Unspecified blinding was used. Results showed that lower achieved LDL-C levels-down to very low levels <20 mg/dL-were associated with a lower risk of the primary efficacy end point (adjusted P(trend)<0.0001 for each end points) and the key secondary efficacy end point (adjusted P(trend)<0.0001 for each end points) with no significant safety concerns.",https://pubmed.ncbi.nlm.nih.gov/36779348/?format=pubmed,
"Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer., Altorki et al., NEJM, 2023/02/13",697,Sublobar resection is an effective alternative to lobectomy for patients with peripheral NSCLC with a tumor size of 2 cm or less and pathologically confirmed node-negative disease in the hilar and mediastinal lymph nodes.,Disease-free survival,"Sublobar resection was noninferior to lobar resection for disease-free survival (hazard ratio for disease recurrence or death, 1.01; 90% confidence interval [CI], 0.83 to 1.24). 5-year disease-free survival was 63.6% (95% CI, 57.9 to 68.8) after sublobar resection and 64.1% (95% CI, 58.5 to 69.0) after lobar resection.",Unspecified,sublobar resection vs. lobar resection,https://pubmed.ncbi.nlm.nih.gov/36780674/?format=pubmed,
"Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer., Altorki et al., NEJM, 2023/02/13",697,Sublobar resection is an effective alternative to lobectomy for patients with peripheral NSCLC with a tumor size of 2 cm or less and pathologically confirmed node-negative disease in the hilar and mediastinal lymph nodes.,Disease-free survival,"Sublobar resection was noninferior to lobar resection for disease-free survival (hazard ratio for disease recurrence or death, 1.01; 90% confidence interval [CI], 0.83 to 1.24). 5-year disease-free survival was 63.6% (95% CI, 57.9 to 68.8) after sublobar resection and 64.1% (95% CI, 58.5 to 69.0) after lobar resection.",Unspecified,sublobar resection vs. lobar resection,https://pubmed.ncbi.nlm.nih.gov/36780674/?format=pubmed,
"Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE., Gaba et al., Circulation, 2023/02/13",,Error,Error,Error,Error,"2) This was a randomized controlled trial with unspecified blinding of 27,564 patients with stable atherosclerotic cardiovascular disease. The study found that lower achieved LDL-C levels-down to very low levels <20 mg/dL-were associated with a lower risk of the primary efficacy end point (composite of cardiovascular death, myocardial infarction, stroke, hospital admission for unstable angina or coronary revascularization) and the key secondary efficacy end point (composite of cardiovascular death, myocardial infarction, or stroke) with no significant safety concerns. The study concluded that lower LDL-C levels are associated with lower risk of cardiovascular outcomes.",https://pubmed.ncbi.nlm.nih.gov/36779348/?format=pubmed,
"Early Extracorporeal CPR for Refractory Out-of-Hospital Cardiac Arrest., Suverein et al., NEJM, 2023/01/31",160,Extracorporeal CPR and conventional CPR had similar effects on survival with a favorable neurologic outcome.,Survival with a favorable neurologic outcome (Cerebral Performance Category score of 1 or 2) at 30 days,"20% in the extracorporeal-CPR group were alive with a favorable neurologic outcome, as compared with 16% in the conventional-CPR group (odds ratio, 1.4; 95% confidence interval, 0.5 to 3.5; P = 0.52)",Unspecified,Extracorporeal CPR vs. Conventional CPR,https://pubmed.ncbi.nlm.nih.gov/36720132/?format=pubmed,
"Early Extracorporeal CPR for Refractory Out-of-Hospital Cardiac Arrest., Suverein et al., NEJM, 2023/01/31",160,Extracorporeal CPR and conventional CPR had similar effects on survival with a favorable neurologic outcome.,Survival with favorable neurologic outcome (Cerebral Performance Category score of 1 or 2) at 30 days,"20% in extracorporeal-CPR group vs. 16% in conventional-CPR group (odds ratio, 1.4; 95% confidence interval, 0.5 to 3.5; P = 0.52)",Unspecified,Extracorporeal CPR vs. Conventional CPR,https://pubmed.ncbi.nlm.nih.gov/36720132/?format=pubmed,
"Implantable Defibrillator System Shock Function, Mortality, and Cause of Death After Magnetic Resonance Imaging., Ra et al., Annals of internal medicine, 2023/01/30",629,Non-MRI-conditional ICDs appropriately treated detected tachyarrhythmias after MRI with no serious adverse effects on device function.,"Arrhythmia detection and treatment, generator or lead exchanges, adverse events, and death","4177 arrhythmia episodes were detected, 97 patients received ICD shocks, 61 patients (10% of total) had 130 spontaneous ventricular tachycardia or fibrillation events terminated by ICD shocks, 210 patients (33% of total) died (median, 1.7 years from MRI to death); 3 had cardiac arrhythmia deaths where shocks were indicated without direct evidence of device dysfunction",Unspecified,Patients with non-MRI-conditional ICDs vs. 813 total MRI examinations,https://pubmed.ncbi.nlm.nih.gov/36716451/?format=pubmed,
"Implantable Defibrillator System Shock Function, Mortality, and Cause of Death After Magnetic Resonance Imaging., Ra et al., Annals of internal medicine, 2023/01/30",629,Non-MRI-conditional ICDs appropriately treated detected tachyarrhythmias after MRI with no serious adverse effects on device function reported after MRI.,"Arrhythmia detection and treatment, generator or lead exchanges, adverse events, and death","10% of total patients had 130 spontaneous ventricular tachycardia or fibrillation events terminated by ICD shocks; 33% of total patients died (median, 1.7 years from MRI to death); 3 had cardiac arrhythmia deaths where shocks were indicated without direct evidence of device dysfunction",Unspecified,Patients with non-MRI-conditional ICDs vs. 813 total MRI examinations,https://pubmed.ncbi.nlm.nih.gov/36716451/?format=pubmed,
"Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial., Mohebbi et al., Lancet, 2023/01/28",,Error,Error,Error,Error,"2) This was a multicentre, single-blind, placebo-controlled, phase 3 trial of 242 adult kidney transplant recipients with metabolic acidosis. The study compared sodium bicarbonate treatment to placebo over 2 years, with the primary outcome being the estimated GFR slope. The results showed no significant difference between the treatment groups (mean difference 0.032 mL/min per 1.73 m2 per year). Therefore, the study concluded that treatment with sodium bicarbonate should not be generally recommended to preserve estimated GFR in kidney transplant recipients with chronic kidney disease who have metabolic acidosis.",https://pubmed.ncbi.nlm.nih.gov/36708734/?format=pubmed,
"Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension. (National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute ) , Shapiro et al., NEJM, 2023/01/23",1563,The two strategies did not result in significantly different mortality rates.,All-cause mortality before discharge home by day 90,14.9%),Unspecified,Restrictive Fluid Strategy vs. Liberal Fluid Strategy,https://pubmed.ncbi.nlm.nih.gov/36688507/?format=pubmed,
"Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension. (National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute ) , Shapiro et al., NEJM, 2023/01/23",1563,Restrictive fluid strategy did not result in significantly lower mortality before discharge home by day 90 than the liberal fluid strategy.,All-cause mortality before discharge home by day 90,"No significant difference between groups (14.0% restrictive fluid group, 14.9% liberal fluid group; estimated difference, -0.9 percentage points; 95% CI, -4.4 to 2.6; P = 0.61)",Unspecified,Restrictive Fluid Strategy vs. Liberal Fluid Strategy,https://pubmed.ncbi.nlm.nih.gov/36688507/?format=pubmed,
"Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. (TRANSFORM-HF) , Mentz et al., JAMA, 2023/01/17",2859,Torsemide did not result in a significant difference in all-cause mortality compared to Furosemide.,All-cause mortality in a time-to-event analysis,"No significant difference in all-cause mortality over 12 months (hazard ratio, 1.02 [95% CI, 0.89-1.18])",Unspecified,Torsemide vs Furosemide,https://pubmed.ncbi.nlm.nih.gov/36648467/?format=pubmed,
"Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. (TRANSFORM-HF) , Mentz et al., JAMA, 2023/01/17",2859,Torsemide did not result in a significant difference in all-cause mortality compared to furosemide.,All-cause mortality in a time-to-event analysis,"No significant difference in all-cause mortality over 12 months (hazard ratio, 1.02 [95% CI, 0.89-1.18])",Unspecified,Torsemide vs. Furosemide,https://pubmed.ncbi.nlm.nih.gov/36648467/?format=pubmed,
"Effect of Remifentanil vs Neuromuscular Blockers During Rapid Sequence Intubation on Successful Intubation Without Major Complications Among Patients at Risk of Aspiration: A Randomized Clinical Trial. ((SFAR)) , Grillot et al., JAMA, 2023/01/03",1150,"Remifentanil was statistically inferior to neuromuscular blockers, but the wide confidence interval around the effect estimate remains compatible with noninferiority and limits conclusions about the clinical relevance of the difference.",Successful tracheal intubation on the first attempt without major complications,"Remifentanil group (66.1%) vs. Neuromuscular Blockers group (71.6%); adjusted difference, -6.1%; 95% CI, -11.6% to -0.5%; P = .37 for noninferiority",Unspecified,Remifentanil vs. Neuromuscular Blockers,https://pubmed.ncbi.nlm.nih.gov/36594947/?format=pubmed,
"Effect of Remifentanil vs Neuromuscular Blockers During Rapid Sequence Intubation on Successful Intubation Without Major Complications Among Patients at Risk of Aspiration: A Randomized Clinical Trial. ((SFAR)) , Grillot et al., JAMA, 2023/01/03",1150,"Remifentanil was statistically inferior to neuromuscular blockers, but the wide confidence interval around the effect estimate remains compatible with noninferiority and limits conclusions about the clinical relevance of the difference.",Successful tracheal intubation on the first attempt without major complications,"Remifentanil was statistically inferior to neuromuscular blockers, with 66.1% successful intubation without major complications in the remifentanil group and 71.6% in the neuromuscular blocker group (adjusted difference, -6.1%; 95% CI, -11.6% to -0.5%).",Unspecified,Remifentanil vs. Neuromuscular Blockers,https://pubmed.ncbi.nlm.nih.gov/36594947/?format=pubmed,
"Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?, Sarma et al., Circulation, 2022/12/16",30,acute reductions in PCWP are insufficient to improve exercise capacity,peak exercise capacity,"nitroglycerin lowered PCWP during submaximal and maximal exercise, but peak oxygen uptake was not changed",Unspecified,placebo and nitroglycerin,https://pubmed.ncbi.nlm.nih.gov/36524474/?format=pubmed,
"Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?, Sarma et al., Circulation, 2022/12/16",30,"Acute reductions in PCWP are insufficient to improve exercise capacity, and further argue that high PCWP during exercise is not by itself a limiting factor for exercise performance in patients with HFpEF.",peak exercise capacity,"Nitroglycerin did not affect oxygen uptake at rest, 20W, or peak (placebo, 1.34+-0.48 versus nitroglycerin, 1.32+-0.46 L/min; drug x exercise P=0.984). Compared with placebo, nitroglycerin lowered stroke volume at rest (-8+-13 mL) and 20W (-7+-11 mL), but not peak exercise (0+-10 mL).",Unspecified,placebo and nitroglycerin,https://pubmed.ncbi.nlm.nih.gov/36524474/?format=pubmed,
"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia., Brown et al., NEJM, 2022/12/13",652,Patients with relapsed or refractory CLL or SLL who received zanubrutinib had longer progression-free survival and fewer cardiac adverse events than those who received ibrutinib.,Progression-Free Survival,"78.4% in the zanubrutinib group and 65.9% in the ibrutinib group at 24 months (hazard ratio for disease progression or death, 0.65; 95% confidence interval, [CI], 0.49 to 0.86; P = 0.002)",Unspecified,Zanubrutinib vs. Ibrutinib,https://pubmed.ncbi.nlm.nih.gov/36511784/?format=pubmed,
"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia., Brown et al., NEJM, 2022/12/13",652,Zanubrutinib was associated with longer progression-free survival and fewer cardiac adverse events than ibrutinib.,Progression-free survival,"78.4% in the zanubrutinib group and 65.9% in the ibrutinib group (hazard ratio for disease progression or death, 0.65; 95% confidence interval, [CI], 0.49 to 0.86; P = 0.002)",Unspecified,Zanubrutinib vs. Ibrutinib,https://pubmed.ncbi.nlm.nih.gov/36511784/?format=pubmed,
"Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease : A Randomized Controlled Trial., Hansen et al., Annals of internal medicine, 2022/12/12",165,"Participants on the LCHF diet had greater improvements in glycemic control and weight compared with those on an HCLF diet, but the changes were not sustained 3 months after intervention.","Glycemic control, serum lipid levels, metabolic markers, and liver biopsies to assess NAFLD","Compared with the HCLF diet, participants on the LCHF diet had greater improvements in hemoglobin A(1c) (mean difference in change, -6.1 mmol/mol [95% CI, -9.2 to -3.0 mmol/mol] or -0.59% [CI, -0.87% to -0.30%]) and lost more weight (mean difference in change, -3.8 kg [CI, -6.2 to -1.4 kg]). Both groups had higher high-density lipoprotein cholesterol and lower triglycerides at 6 months. Changes in low-density lipoprotein cholesterol were less favorable in the LCHF diet group than in the HCLF diet group (mean difference in change, 0.37 mmol/L [CI, 0.17 to 0.58 mmol/L] or 14.3 mg/dL [CI, 6.6 to 22.4 mg/dL]). No statistically significant between-group changes were detected in the assessment of NAFLD. Changes were not sustained at the 9-month follow-up.",Unspecified,LCHF diet vs. HCLF diet,https://pubmed.ncbi.nlm.nih.gov/36508737/?format=pubmed,
"Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD., Schechter et al., Annals of internal medicine, 2022/12/05",4304,Dapagliflozin reduced the risk for hospitalization for any cause in patients with CKD with and without type 2 diabetes.,Risk for hospitalization for any cause,"Dapagliflozin reduced risk for a first hospitalization (hazard ratio, 0.84 [95% CI, 0.75 to 0.94]) and all hospitalizations or death (rate ratio, 0.79 [CI, 0.70 to 0.89])",Double-blind,Dapagliflozin vs. Placebo,https://pubmed.ncbi.nlm.nih.gov/36469914/?format=pubmed,
"Comparative Effectiveness of Team-Based Care With and Without a Clinical Decision Support System for Diabetes Management : A Cluster Randomized Trial., Shi et al., Annals of internal medicine, 2022/12/05",,Error,Error,Error,Error,"This was a cluster randomized trial of 11,132 patients aged 50 years or older with uncontrolled diabetes and comorbid conditions, comparing team-based care with a CDSS to team-based care alone. The primary outcome was mean reductions in hemoglobin A(1c) (HbA(1c)) level, low-density lipoprotein cholesterol (LDL-C) level, and systolic BP over 18 months and the proportion of participants with all 3 risk factors controlled at 18 months. Results showed that team-based care with a CDSS significantly reduced HbA(1c) levels, LDL-C levels, and systolic BP by -0.9 percentage point, -0.49 mmol/L (-19.0 mg/dL), and -9.1 mm Hg, respectively, compared to team-based care alone, which reduced HbA(1c) levels, LDL-C levels, and systolic BP by -0.6 percentage point, -0.32 mmol/L (-12.5 mg/dL), and -7.5 mm Hg, respectively. The proportion of patients with controlled HbA(1c), LDL-C, and systolic BP was 16.9% in team-based care with a CDSS and 13.0% in team-based care alone.",https://pubmed.ncbi.nlm.nih.gov/36469915/?format=pubmed,
"Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD., Schechter et al., Annals of internal medicine, 2022/12/05",4304,Dapagliflozin reduced the risk for hospitalization for any cause in patients with CKD with and without type 2 diabetes.,Risk for hospitalization for any cause,"Dapagliflozin reduced risk for a first hospitalization (hazard ratio, 0.84 [95% CI, 0.75 to 0.94]) and all hospitalizations or death (rate ratio, 0.79 [CI, 0.70 to 0.89])",Double-blind,Dapagliflozin vs. Placebo,https://pubmed.ncbi.nlm.nih.gov/36469914/?format=pubmed,
"Comparative Effectiveness of Team-Based Care With and Without a Clinical Decision Support System for Diabetes Management : A Cluster Randomized Trial., Shi et al., Annals of internal medicine, 2022/12/05","11,132","Team-based care with a CDSS significantly reduced cardiovascular risk factors in patients with diabetes, but the effect was modest.","Mean reductions in hemoglobin A(1c) (HbA(1c)) level, low-density lipoprotein cholesterol (LDL-C) level, and systolic BP over 18 months and the proportion of participants with all 3 risk factors controlled at 18 months","HbA(1c) levels, LDL-C levels, and systolic BP significantly decreased by -0.9 percentage point (95% CI, -0.9 to -0.8 percentage point), -0.49 mmol/L (CI, -0.53 to -0.45 mmol/L) (-19.0 mg/dL [CI, -20.4 to -17.5 mg/dL]), and -9.1 mm Hg (CI, -9.9 to -8.3 mm Hg), respectively, in team-based care with a CDSS and by -0.6 percentage point (CI, -0.7 to -0.5 percentage point), -0.32 mmol/L (CI, -0.35 to -0.29 mmol/L) (-12.5 mg/dL [CI, -13.6 to -11.3 mg/dL]), and -7.5 mm Hg (CI, -8.4 to -6.6 mm Hg), respectively, in team-based care alone. Net differences were -0.2 percentage point (CI, -0.3 to -0.1 percentage point) for HbA(1c) level, -0.17 mmol/L (CI, -0.21 to -0.12 mmol/L) (-6.5 mg/dL [CI, -8.3 to -4.6 mg/dL]) for LDL-C level, and -1.5 mm Hg (CI, -2.8 to -0.3 mm Hg) for systolic BP. The proportion of patients with controlled HbA(1c), LDL-C, and systolic BP was 16.9% (CI, 15.7% to 18.2%) in team-based care with a CDSS and 13.0% (CI, 11.7% to 14.3%) in team-based care alone.",Unspecified,Team-based care with a CDSS (5475) vs. team-based care alone (5657),https://pubmed.ncbi.nlm.nih.gov/36469915/?format=pubmed,
"Comparative Effectiveness of Team-Based Care With and Without a Clinical Decision Support System for Diabetes Management : A Cluster Randomized Trial., Shi et al., Annals of internal medicine, 2022/12/05","11,132","Team-based care with a CDSS significantly reduced cardiovascular risk factors in patients with diabetes, but the effect was modest.","Mean reductions in hemoglobin A(1c) (HbA(1c)) level, low-density lipoprotein cholesterol (LDL-C) level, and systolic BP over 18 months and the proportion of participants with all 3 risk factors controlled at 18 months","HbA(1c) levels, LDL-C levels, and systolic BP significantly decreased by -0.9 percentage point, -0.49 mmol/L (-19.0 mg/dL), and -9.1 mm Hg, respectively, in team-based care with a CDSS and by -0.6 percentage point, -0.32 mmol/L (-12.5 mg/dL), and -7.5 mm Hg, respectively, in team-based care alone. The proportion of patients with controlled HbA(1c), LDL-C, and systolic BP was 16.9% in team-based care with a CDSS and 13.0% in team-based care alone.",Unspecified,Team-based care with a CDSS (5475) and team-based care alone (5657),https://pubmed.ncbi.nlm.nih.gov/36469915/?format=pubmed,
"Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD., Schechter et al., Annals of internal medicine, 2022/12/05",4304,Dapagliflozin reduced the risk for hospitalization for any cause in patients with CKD with and without type 2 diabetes.,Risk for first hospitalization and all hospitalizations or death,"Dapagliflozin reduced risk for first hospitalization (hazard ratio, 0.84 [95% CI, 0.75 to 0.94]) and all hospitalizations or death (rate ratio, 0.79 [CI, 0.70 to 0.89])",Double-blind,Dapagliflozin vs. Placebo,https://pubmed.ncbi.nlm.nih.gov/36469914/?format=pubmed,
"Progression of Atrial Fibrillation after Cryoablation or Drug Therapy. (EARLY-AF) , Andrade et al., NEJM, 2022/11/07",303,Initial treatment of paroxysmal atrial fibrillation with catheter cryoballoon ablation was associated with a lower incidence of persistent atrial fibrillation or recurrent atrial tachyarrhythmia over 3 years of follow-up than initial use of antiarrhythmic drugs.,Incidence of Persistent Atrial Fibrillation or Recurrent Atrial Tachyarrhythmia,"3 patients (1.9%) in the ablation group had an episode of persistent atrial fibrillation, as compared with 11 patients (7.4%) in the antiarrhythmic drug group (hazard ratio, 0.25; 95% CI, 0.09 to 0.70). Recurrent atrial tachyarrhythmia occurred in 87 patients in the ablation group (56.5%) and in 115 in the antiarrhythmic drug group (77.2%) (hazard ratio, 0.51; 95% CI, 0.38 to 0.67).",Unspecified,Cryoballoon Ablation vs. Antiarrhythmic Drug Therapy,https://pubmed.ncbi.nlm.nih.gov/36342178/?format=pubmed,
"Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study., Kang et al., Circulation, 2022/11/07",5438,Clopidogrel monotherapy compared with aspirin monotherapy was associated with lower rates of the composite net clinical outcome in patients without clinical events for 12+-6 months after percutaneous coronary intervention with drug-eluting stents.,"Composite of all-cause death, nonfatal myocardial infarction, stroke, readmission attributable to acute coronary syndrome, and Bleeding Academic Research Consortium type 3 or greater bleeding","12.8% in the clopidogrel group and 16.9% in the aspirin group (hazard ratio, 0.74 [95% CI, 0.63-0.86]; P<0.001)",Unspecified,Clopidogrel (75 mg once daily) vs Aspirin (100 mg once daily),https://pubmed.ncbi.nlm.nih.gov/36342475/?format=pubmed,
"Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study., Foulkes et al., Circulation, 2022/11/07",104,"12 months of ExT did not attenuate functional disability, but provided large, clinically meaningful benefits on VO(2)peak and cardiac reserve.",Functional Disability,"ExT attenuated functional disability at 4 months (odds ratio, 0.32 [95% CI, 0.11-0.94]; P=0.03) but not at 12 months (odds ratio, 0.27 [95% CI, 0.06-1.12]; P=0.07)",Unspecified,Exercise Training (ExT) vs. Usual Care (UC),https://pubmed.ncbi.nlm.nih.gov/36342348/?format=pubmed,
"Duration of Device-Based Fever Prevention after Cardiac Arrest., Hassager et al., NEJM, 2022/11/07",393 and 396,Active device-based fever prevention for 36 or 72 hours after cardiac arrest did not result in significantly different percentages of patients dying or having severe disability or coma.,Composite of death from any cause or hospital discharge with a Cerebral Performance Category of 3 or 4 within 90 days after randomization,"32.3% in the 36-hour group and 33.6% in the 72-hour group (hazard ratio, 0.99; 95% confidence interval, 0.77 to 1.26; P = 0.70)",Unspecified,Device-based temperature control targeting 36degC for 24 hours followed by targeting of 37degC for either 12 or 48 hours,https://pubmed.ncbi.nlm.nih.gov/36342119/?format=pubmed,
"Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study., Foulkes et al., Circulation, 2022/11/07",104,"Exercise Training (ExT) provided large, clinically meaningful benefits on functional disability and cardiac reserve in women with early-stage breast cancer undergoing anthracycline-based chemotherapy (AC).",Functional disability,"ExT attenuated functional disability at 4 months (odds ratio, 0.32 [95% CI, 0.11-0.94]; P=0.03) but not at 12 months (odds ratio, 0.27 [95% CI, 0.06-1.12]; P=0.07). In a per-protocol analysis, functional disability was prevented entirely at 12 months among participants adherent to ExT (ExT, 0% versus UC, 20%; P=0.005).",Unspecified,Exercise Training (ExT) vs. Usual Care (UC),https://pubmed.ncbi.nlm.nih.gov/36342348/?format=pubmed,
"Progression of Atrial Fibrillation after Cryoablation or Drug Therapy. (EARLY-AF) , Andrade et al., NEJM, 2022/11/07",303,Catheter cryoballoon ablation was associated with a lower incidence of persistent atrial fibrillation or recurrent atrial tachyarrhythmia over 3 years of follow-up than initial use of antiarrhythmic drugs.,Incidence of persistent atrial fibrillation or recurrent atrial tachyarrhythmia,"3 patients (1.9%) in the ablation group had an episode of persistent atrial fibrillation, as compared with 11 patients (7.4%) in the antiarrhythmic drug group (hazard ratio, 0.25; 95% CI, 0.09 to 0.70). Recurrent atrial tachyarrhythmia occurred in 87 patients in the ablation group (56.5%) and in 115 in the antiarrhythmic drug group (77.2%) (hazard ratio, 0.51; 95% CI, 0.38 to 0.67).",Unspecified,cryoballoon ablation vs. antiarrhythmic drug therapy,https://pubmed.ncbi.nlm.nih.gov/36342178/?format=pubmed,
"Trial of an Intervention to Improve Acute Heart Failure Outcomes. (COACH) , Lee et al., NEJM, 2022/11/07",5452,The use of a hospital-based strategy to support clinical decision making and rapid follow-up led to a lower risk of the composite of death from any cause or hospitalization for cardiovascular causes within 30 days than usual care.,Composite of Death from Any Cause or Hospitalization for Cardiovascular Causes within 30 Days,"Adjusted Hazard Ratio of 0.88 (95% CI, 0.78 to 0.99; P = 0.04)",Unspecified,Control Phase (Usual Care) vs. Intervention Phase (Point-of-Care Algorithm),https://pubmed.ncbi.nlm.nih.gov/36342109/?format=pubmed,
"Survival After Invasive or Conservative Management of Stable Coronary Disease. (ISCHEMIA-EXTEND) , Hochman et al., Circulation, 2022/11/06",5179,"An initial invasive strategy did not improve all-cause mortality, but it did reduce the risk of cardiovascular mortality and increase the risk of noncardiovascular mortality.",All-cause mortality,"No difference in all-cause mortality with an initial invasive strategy compared with an initial conservative strategy, but there was lower risk of cardiovascular mortality (7-year rate, 6.4%) and higher risk of noncardiovascular mortality (7-year rate, 5.6%) with an initial invasive strategy during a median follow-up of 5.7 years",Unspecified,Initial invasive strategy vs. initial conservative strategy,https://pubmed.ncbi.nlm.nih.gov/36335918/?format=pubmed,
"A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study., Reinecke et al., Circulation, 2022/11/06",,Error,Error,Error,Error,"2) This was a randomized, prospective, open-blinded endpoint assessment trial (PROBE) with an unspecified study blinding, involving 97 patients with atrial fibrillation on hemodialysis. The study compared the safety and efficacy of apixaban (2.5 mg BID) to the Vitamin K antagonist phenprocoumon (international normalized ratio, 2.0 to 3.0). The primary safety outcome was defined by a first event of major bleeding, clinically relevant nonmajor bleeding, or all-cause death, while the primary efficacy outcome was a composite of ischemic stroke, all-cause death, myocardial infarction, and deep vein thrombosis or pulmonary embolism. Results showed no significant differences between the two groups (Hazard Ratio 0.93 [95% CI, 0.53-1.65]; P(noninferiority)=0.157).",https://pubmed.ncbi.nlm.nih.gov/36335915/?format=pubmed,
"Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial., Connelly et al., Circulation, 2022/11/06",,Error,Error,Error,Error,"2) This was a randomized controlled trial (RCT) with an unspecified study blinding, involving 169 participants (40-80 years old) without diabetes but with risk factors for adverse cardiac remodeling. Participants were randomly assigned to either empagliflozin (10 mg/d) or placebo for 6 months. The primary outcome was the 6-month change in Left Ventricular Mass Indexed (LVMi) to baseline body surface area. Results showed that there was no difference in LVMi at 6 months in the empagliflozin group versus placebo group adjusted for baseline LVMi (-0.30 g/m(2); P=0.74).",https://pubmed.ncbi.nlm.nih.gov/36335517/?format=pubmed,
"Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial., Connelly et al., Circulation, 2022/11/06",,Error,Error,Error,Error,"2) This was a randomized, double-blind (unspecified), 6-month study of 169 individuals, 40 to 80 years of age, without diabetes but with risk factors for adverse cardiac remodeling. Participants were randomly assigned to empagliflozin (10 mg/d; n=85) or placebo (n=84). The primary outcome was the 6-month change in left ventricular (LV) mass indexed (LVMi) to baseline body surface area. Results showed that there was no meaningful difference between the two groups, with a difference in LVMi of -0.30 g/m(2) (-2.1 to 1.5 g/m(2); P=0.74).",https://pubmed.ncbi.nlm.nih.gov/36335517/?format=pubmed,
"Survival After Invasive or Conservative Management of Stable Coronary Disease. (ISCHEMIA-EXTEND) , Hochman et al., Circulation, 2022/11/06",5179,"No difference in all-cause mortality between groups, but lower risk of cardiovascular mortality and higher risk of noncardiovascular mortality with an initial invasive strategy.",All-cause mortality,"No difference in all-cause mortality between groups (7-year rate, 12.7% in invasive strategy, 13.4% in conservative strategy; adjusted hazard ratio, 1.00 [95% CI, 0.85-1.18])",Unspecified,Initial invasive strategy added to guideline-directed medical therapy vs. conservative strategy,https://pubmed.ncbi.nlm.nih.gov/36335918/?format=pubmed,
"Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial. (ECMO-CS) , Ostadal et al., Circulation, 2022/11/06",117,Immediate implementation of VA-ECMO in patients with rapidly deteriorating or severe cardiogenic shock did not improve clinical outcomes compared with an early conservative strategy that permitted downstream use of VA-ECMO in case of worsening hemodynamic status.,"Composite of death from any cause, resuscitated circulatory arrest, and implementation of another mechanical circulatory support device at 30 days","37 (63.8%) and 42 (71.2%) patients in the immediate VA-ECMO and the no early VA-ECMO groups, respectively (hazard ratio, 0.72 [95% CI, 0.46-1.12]; P=0.21)",Unspecified,immediate VA-ECMO vs. no immediate VA-ECMO,https://pubmed.ncbi.nlm.nih.gov/36335478/?format=pubmed,
"Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial. (OPTION) , Wu et al., Circulation, 2022/11/06",,Error,Error,Error,Error,"1 ratio to receive either indobufen-based DAPT or conventional DAPT. The primary end point was a 1-year composite of cardiovascular death, nonfatal myocardial infarction, ischemic stroke, definite or probable stent thrombosis, or Bleeding Academic Research Consortium criteria type 2, 3, or 5 bleeding. The results showed that indobufen-based DAPT was noninferior to conventional DAPT in terms of the primary end point (absolute difference, -1.63%; P(noninferiority)<0.001; hazard ratio, 0.73 [95% CI, 0.56-0.94]; P=0.015) and was associated with a lower occurrence of Bleeding Academic Research Consortium criteria type 2, 3, or 5 bleeding events (2.97% versus 4.71%; hazard ratio, 0.63 [95% CI, 0.46-0.85]; P=0.002).",https://pubmed.ncbi.nlm.nih.gov/36335890/?format=pubmed,
"Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks., Desai et al., Circulation, 2022/11/06",,Error,Error,Error,Error,"2) This was a double-blind, randomized placebo-controlled multicenter trial of 112 patients with obstructive hypertrophic cardiomyopathy who were referred for septal reduction therapy. The study compared mavacamten to placebo, with a crossover to mavacamten after 16 weeks for the placebo group. The primary outcome was the proportion of patients proceeding with SRT or remaining guideline eligible at 32 weeks. Results showed that 10.7% of patients in the mavacamten group and 13.5% of patients in the placebo cross-over group met SRT guideline criteria or elected to undergo SRT, with a sustained reduction in the left ventricular outflow tract gradient in both groups.",https://pubmed.ncbi.nlm.nih.gov/36335531/?format=pubmed,
"Empagliflozin in Patients with Chronic Kidney Disease. (EMPA-KIDNEY) , Herrington et al., NEJM, 2022/11/04",6609,Empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo.,Progression of kidney disease or death from cardiovascular causes,"13.1% in the empagliflozin group and 16.9% in the placebo group (hazard ratio, 0.72; 95% CI, 0.64 to 0.82; P<0.001)",Unspecified,empagliflozin vs. placebo,https://pubmed.ncbi.nlm.nih.gov/36331190/?format=pubmed,
"Empagliflozin in Patients with Chronic Kidney Disease. (EMPA-KIDNEY) , Herrington et al., NEJM, 2022/11/04",6609,Empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo.,Progression of kidney disease or death from cardiovascular causes,"13.1% in the empagliflozin group and 16.9% in the placebo group (hazard ratio, 0.72; 95% CI, 0.64 to 0.82; P<0.001)",Unspecified,empagliflozin (10 mg once daily) vs. matching placebo,https://pubmed.ncbi.nlm.nih.gov/36331190/?format=pubmed,
